title: Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Bloch
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination; D000068896:Canagliflozin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use; D056687:Off-Label Use; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D000959:Antihypertensive Agents; D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C529054:dapagliflozin; D008687:Metformin; C570240:empagliflozin